NCT01523067View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Essential Hypertension
Interventions
DRUG

Vasomera (PB1046)

Single dose of Vasomera

DRUG

0.9% Sodium Chloride

Placebo injection

Trial Locations (5)

36207

Pinnacle Research, Anniston

37920

New Orleans Center for Clinical Research, Knoxville

55114

Prism Research Inc., Saint Paul

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Clinical Research, Renton

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY